Finance

Lists
4543:TYO
Terumo Corp
2 277,50 JP¥
+0,26%
(+6,00) 1D
29 қыр., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4543...
Open
2 296 JP¥
High
2 306 JP¥
Low
2 253 JP¥
Mkt. cap
3,37 трлн
Avg. vol.
4,73 млн
Volume
4,84 млн
Dividend
1,32%
Quarterly dividend
7 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
20,43
52-wk high
2 689 JP¥
52-wk low
1 900 JP¥
EPS
111 JP¥
Shares outstanding
370,59 млн
No. of employees
31 мың
Open
2 296 JP¥
High
2 306 JP¥
Low
2 253 JP¥
Mkt. cap
3,37 трлн
Avg. vol.
4,73 млн
Volume
4,84 млн
Dividend
1,32%
Quarterly dividend
7 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
20,43
52-wk high
2 689 JP¥
52-wk low
1 900 JP¥
EPS
111 JP¥
Shares outstanding
370,59 млн
No. of employees
31 мың
News stories
From web sources and news partners
Profile
Terumo Corporation was founded in 1921 as Red Line Thermometer Corporation by a group of medical scientists led by Dr. Kitasato Shibasaburō to produce medical thermometers in Japan. The company's first product was "Jintan Taionkei", the first Japanese-made thermometer available for sale, and it has since expanded into a medical devices manufacturer, producing medical disposables, cardiovascular systems and diabetes care products. In 1971, Terumo opened its first overseas office in the United States. Since then, the company has established subsidiaries in Europe, South America, China, India, Philippines, Vietnam, Thailand, Australia and México. The company later expanded its product range to include coronary stents and catheters, and acquired, among others, the cardiovascular specialty companies Vascutek and Microvention in 2002 and 2006 respectively. Wikipedia
About Terumo Corp
CEO-
Employees31,2 мың
Founded1921 ж. 17 қыр.
HeadquartersShibuya, Токио, Жапония
SectorMedical device
Last report
2026 ж. 07 там.
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
311,81 млрд / 299,25 млрд
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
274,96 млрд
296,63 млрд
300,32 млрд
311,81 млрд
Cost of goods sold
127,97 млрд
143,44 млрд
149,06 млрд
133,27 млрд
Cost of revenue
127,97 млрд
143,44 млрд
149,06 млрд
133,27 млрд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
97,88 млрд
105,26 млрд
107,66 млрд
109,70 млрд
Operating expense
101,90 млрд
109,31 млрд
98,62 млрд
89,06 млрд
Total operating expenses
229,87 млрд
252,74 млрд
247,68 млрд
222,33 млрд
Operating income
45,10 млрд
43,88 млрд
52,64 млрд
89,48 млрд
Other non operating income
-1,00 млн
2,00 млн
-409,00 млн
-4,00 млн
EBT including unusual items
45,95 млрд
45,38 млрд
31,66 млрд
90,32 млрд
EBT excluding unusual items
45,95 млрд
45,38 млрд
52,86 млрд
90,32 млрд
Income tax expense
10,90 млрд
12,72 млрд
5,30 млрд
19,89 млрд
Effective tax rate
23,72%
28,04%
16,73%
22,03%
Other operating expenses
4,02 млрд
4,05 млрд
-9,05 млрд
-20,64 млрд
Net income
35,05 млрд
32,65 млрд
26,37 млрд
70,43 млрд
Net profit margin
12,75%
11,01%
8,78%
22,59%
Earnings per share
-
-
-
-
Interest and investment income
1,02 млрд
2,21 млрд
-
2,38 млрд
Interest expense
-18,00 млн
-463,00 млн
-1,32 млрд
-1,48 млрд
Net interest expenses
1,00 млрд
1,75 млрд
-1,32 млрд
905,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
66,76 млрд
69,98 млрд
79,07 млрд
116,67 млрд
Gain or loss from assets sale
4,72 млрд
154,00 млн
188,00 млн
12,00 млн
AI content may include mistakes. Learn more
Google қолданбалары